K Koch1, W Klapper2. 1. Institut für Pathologie, Sektion Hämatopathologie und Lymphknotenregister, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus 14, 24113, Kiel, Deutschland. karoline.koch@uksh.de. 2. Institut für Pathologie, Sektion Hämatopathologie und Lymphknotenregister, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus 14, 24113, Kiel, Deutschland.
Abstract
BACKGROUND: The World Health Organization (WHO) is planning an update of the WHO classification of malignant lymphomas. OBJECTIVE: To present new findings concerning the diagnostics and subclassification of malignant lymphomas. MATERIAL AND METHODS: A selective literature search ( http://www.ncbi.nlm.nih.gov ) was carried out and combined with the practical experiences of the authors in clinicopathological diagnostics. RESULTS: In recent years an increasing number of early lesions of malignant lymphomas have been described but the potential malignancy of these lesions is at least for some entities still uncertain. Newly defined entities have been described within the group of T-cell lymphomas and prognostic subgroups have been identified in the heterogeneous group of diffuse large B-cell lymphomas. Detection of mutations facilitates the differential diagnostics of morphologically similar diseases and can be an important component of the diagnostics. CONCLUSION: Recent scientific insights are being included more and more into the diagnostics of lymphomas. The update of the WHO classification is a consequence of these developments.
BACKGROUND: The World Health Organization (WHO) is planning an update of the WHO classification of malignant lymphomas. OBJECTIVE: To present new findings concerning the diagnostics and subclassification of malignant lymphomas. MATERIAL AND METHODS: A selective literature search ( http://www.ncbi.nlm.nih.gov ) was carried out and combined with the practical experiences of the authors in clinicopathological diagnostics. RESULTS: In recent years an increasing number of early lesions of malignant lymphomas have been described but the potential malignancy of these lesions is at least for some entities still uncertain. Newly defined entities have been described within the group of T-cell lymphomas and prognostic subgroups have been identified in the heterogeneous group of diffuse large B-cell lymphomas. Detection of mutations facilitates the differential diagnostics of morphologically similar diseases and can be an important component of the diagnostics. CONCLUSION: Recent scientific insights are being included more and more into the diagnostics of lymphomas. The update of the WHO classification is a consequence of these developments.
Entities:
Keywords:
BRAF protein, human; In situ lymphoma; Lymphoma, T-cell, peripheral; Lymphoma, large B-cell, diffuse; MYD88 protein
Authors: W Kraan; M van Keimpema; H M Horlings; E J M Schilder-Tol; M E C M Oud; L A Noorduyn; P M Kluin; M J Kersten; M Spaargaren; S T Pals Journal: Leukemia Date: 2013-11-20 Impact factor: 11.528
Authors: Karthik A Ganapathi; Stefania Pittaluga; Oreofe O Odejide; Arnold S Freedman; Elaine S Jaffe Journal: Haematologica Date: 2014-09 Impact factor: 9.941
Authors: Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini Journal: N Engl J Med Date: 2011-06-11 Impact factor: 91.245